Applications for positron emission mammography

Weinberg, I.

doi:10.1016/s1120-1797(06)80045-1

Cited by 21 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other forms of PET scanners such as the Positron Emission Mammography has shown high accuracy and appears useful in biopsy guidance, surgical planning and surveillance for recurrence 30, but is unsuitable for patients with cutaneous loco-regional recurrence of breast cancer as most of these have had mastectomy.…”

Section: Discussionmentioning

confidence: 99%

Dual time point imaging fluorine-18 flourodeoxyglucose positron emission tomography for evaluation of large loco-regional recurrences of breast cancer treated with electrochemotherapy

Matthiessen¹,

Johannesen²,

Skougaard³

et al. 2013

Radiology and Oncology

View full text Add to dashboard Cite

BackgroundElectrochemotherapy is a local anticancer treatment very efficient for treatment of small cutaneous metastases. The method is now being investigated for large cutaneous recurrences of breast cancer that are often confluent masses of malignant tumour with various degrees of inflammation. To this end 18-Flourine-Flourodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) could be a method for response evaluation. However, a standard FDG-PET/CT scan cannot differentiate inflammatory tissue from malignant tissue. Dual point time imaging (DTPI) FDG-PET has the potential of doing so. The purpose of this study was to investigate if DTPI FDG-PET/CT could assess response to electrochemotherapy and to assess the optimal timing of imaging.Patients and methodsWithin a phase II clinical trial 11 patients with cutaneous recurrences had FDG-PET/CT scans at three time points: 60 min, 120 min and 180 min after FDG injection. The scans were performed before and 3 weeks after electrochemotherapy.ResultsA significant reduction in maximum standard uptake value at 60 min post injection was seen after treatment. Furthermore a change in the FDG uptake pattern was observed; from increasing uptake in up to 180 min post injection before treatment to stabilization of FDG uptake at 120 min post injection after treatment. The change in FDG uptake pattern over time lead to change of response in three target lesions; two lesions changed from stable metabolic disease to partial metabolic response and one lesion changed from partial metabolic response to stable metabolic disease. To ensure detection of the change in uptake pattern, scanning 60 and 180 min post injection seems optimal.ConclusionsThe present study shows that FDG-PET/CT 60 and 180 min after tracer injection is a promising tool for response evaluation of cutaneous recurrences of breast cancer treated with electrochemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Dual time point imaging fluorine-18 flourodeoxyglucose positron emission tomography for evaluation of large loco-regional recurrences of breast cancer treated with electrochemotherapy

Matthiessen¹,

Johannesen²,

Skougaard³

et al. 2013

Radiology and Oncology

View full text Add to dashboard Cite

show abstract

“…A dedicated small-parts system like PEM has high spatial resolution, and in breast applications, has been shown to have comparable sensitivity and specificity to MRI for breast lesions [44]. The small PEM detector separation reduces resolution loss due to annihilation photon noncolinearity [28]. Breast-only devices suffer from much less attenuation loss than WB scanners, with up to a tenfold increase in count efficiency [41].…”

Section: Discussionmentioning

confidence: 99%

“…FDG accumulation in inflammatory conditions is likely secondary to the enhanced glycolytic metabolism in inflammatory cellular infiltrates including activated macrophages, neutrophils and lymphocytes [27]. Small field-of-view (FOV) positron emission mammography (PEM) systems designed for breast imaging have better spatial resolution than conventional larger FOV whole-body (WB) PET/CT systems [28]. Such systems are also less costly than WBPET systems.…”

Section: Introductionmentioning

confidence: 99%

18F-FDG PET of the hands with a dedicated high-resolution PEM system (arthro-PET): correlation with PET/CT, radiography and clinical parameters

Mhlanga

Carrino

Lodge

et al. 2014

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose The aim of this study was to prospectively determine the feasibility and compare the novel use of a positron emission mammography (PEM) scanner with standard PET/CT for evaluating hand osteoarthritis (OA) with 18F-FDG. Methods Institutional review board approval and written informed consent were obtained for this HIPAA-compliant prospective study in which 14 adults referred for oncological 18F-FDG PET/CT underwent dedicated hand PET/CT followed by arthro-PET using the PEM device. Hand radiographs were obtained and scored for the presence and severity of OA. Summed qualitative and quantitative joint glycolytic scores for each modality were compared with the findings on plain radiography and clinical features. Results Eight patients with clinical and/or radiographic evidence of OA comprised the OA group (mean age 73±7.7 years). Six patients served as the control group (53.7±9.3 years). Arthro-PET quantitative and qualitative joint glycolytic scores were highly correlated with PET/CT findings in the OA patients (r=0.86. p =0.007; r=0.94, p=0.001). Qualitative arthro-PET and PET/CT joint scores were significantly higher in the OA patients than in controls (38.7±6.6 vs. 32.2±0.4, p=0.02; 37.5±5.4 vs. 32.2±0.4, p=0.03, respectively). Quantitative arthro-PET and PET/CT maximum SUV-lean joint scores were higher in the OA patients, although they did not reach statistical significance (20.8±4.2 vs. 18±1.8, p= 0.13; 22.8±5.38 vs. 20.1±1.54, p=0.21). By definition, OA patients had higher radiographic joint scores than controls (30.9±31.3 vs. 0, p=0.03). Conclusion Hand imaging using a small field of view PEM system (arthro-PET) with FDG is feasible, performing comparably to PET/CT in assessing metabolic joint activity. Arthro-PET and PET/CT showed higher joint FDG uptake in OA. Further exploration of arthro-PET in arthritis management is warranted.

show abstract

“…Molecular breast imaging (MBI) is one of several promising supplemental techniques, along with other technologies such as positron emission mammography [14,15], ultra-fast MRI [16] and contrast enhanced CT [17] that may be viable alternatives to mammography. In considering what qualifies as a suitable supplemental technique, there are a number of criteria that are highly desirable.…”

Section: The Need For Supplemental Screening Techniquesmentioning

confidence: 99%

Molecular Breast Imaging: An Emerging Modality for Breast Cancer Screening

O’Connor¹

2015

Breast Cancer Manag.

View full text Add to dashboard Cite

SUMMARY Screening mammography is recognized as an imperfect imaging tool that performs poorly in women with dense breast tissue – a limitation which has driven demand for supplemental screening techniques. One potential supplemental technique is molecular breast imaging (MBI). Significant improvements in gamma camera technology allow MBI to be performed at low radiation doses, comparable with those of tomosynthesis and mammography. A recent screening trial in women with dense breast tissue yielded a cancer detection rate of 3.2 per 1000 for mammography alone and 12.0 per 1000 for the combination of mammography and MBI. MBI also demonstrated a lower recall rate than that of mammography. MBI is a promising supplemental screening technique in women with dense breast tissue.

show abstract

Applications for positron emission mammography

Cited by 21 publications

References 11 publications

Dual time point imaging fluorine-18 flourodeoxyglucose positron emission tomography for evaluation of large loco-regional recurrences of breast cancer treated with electrochemotherapy

Dual time point imaging fluorine-18 flourodeoxyglucose positron emission tomography for evaluation of large loco-regional recurrences of breast cancer treated with electrochemotherapy

18F-FDG PET of the hands with a dedicated high-resolution PEM system (arthro-PET): correlation with PET/CT, radiography and clinical parameters

Molecular Breast Imaging: An Emerging Modality for Breast Cancer Screening

Contact Info

Product

Resources

About